# GeneChem: portfolio, investments and team > GeneChem is a growth equity based in Canada. 21 investments on record, latest May 2014. Portfolio, stages, co-investors and team. Source: https://millionrounds.com/fund/genechem (Millionrounds; every figure on the page links to its filing or article) Canada · [Investor](https://millionrounds.com/investors) # GeneChem No cheque observed since May 2014, after 21 earlier cheques, and the website is dead. Dormant Growth equity Series B Series A Series C E-Commerce Energy Health Care Cheques on record **0%** of best year **0** **cheques in 12 months**, 21 on record Since the last cheque **4547** days **00** hrs **00** min **00** sec Median round **$20M** Rounds led **0 of 21** Exits **6 from the portfolio** Mostly in **United States, 86%** Pitch GeneChem ## GeneChem highlights - 01 21 rounds on record - 02 Mostly Series B and Series A: 67% of its rounds - 03 6 exits from the portfolio ## What they do - **Type:** Growth equity (from a list, unverified) - **Cheque size:** Not stated - **Sectors:** E-Commerce Energy Health Care - **Based in:** Montreal, Canada - **Cold pitches:** Not stated ## The record Every round we can evidence, newest first **21 appearances** - **2014** 1 round - **May** **[Sorbent Therapeutics](https://millionrounds.com/company/sorbent-therapeutics)** Series D · US **$6.5M** With 4 others - **2013** 1 round - **Jun** **[Akebia Therapeutics](https://millionrounds.com/company/akebia-therapeutics)** Series C · US · finsmes.com **$41M** With 8 others - **2012** 3 rounds - **Nov** **[Alethia BioTherapeutics](https://millionrounds.com/company/alethia-biotherapeutics)** Series B · CA · finance.yahoo.com **$4.7M** With 2 others - **Aug** **[Aerpio Therapeutics](https://millionrounds.com/company/aerpio-therapeutics)** Series A · US · finsmes.com **$27M** With 6 others - **Jan** **[Akebia Therapeutics](https://millionrounds.com/company/akebia-therapeutics)** Series B · US · finsmes.com **$4.1M** With 7 others - **2011** 3 rounds - **Jun** **[Sorbent Therapeutics](https://millionrounds.com/company/sorbent-therapeutics)** Series B · US · money.msn.com **$36M** With 4 others - **Apr** **[Akebia Therapeutics](https://millionrounds.com/company/akebia-therapeutics)** Series B · US · akebia.com **$22M** With 6 others - **Feb** **[Conatus Pharmaceuticals](https://millionrounds.com/company/conatus-pharmaceuticals)** Series B · US · pharmalive.com **$20M** With 5 others - **2010** 3 rounds - **Sept** **[Sorbent Therapeutics](https://millionrounds.com/company/sorbent-therapeutics)** Series B · US · fis.dowjones.com **$22M** With 3 others - **Sept** **[Alethia BioTherapeutics](https://millionrounds.com/company/alethia-biotherapeutics)** Series A · CA · fis.dowjones.com **$9.2M** With 3 others - **Feb** **[Altair Therapeutics](https://millionrounds.com/company/altair-therapeutics)** Series B · US · onbiovc.com **$17M** With 3 others - **2008** 2 rounds - **Sept** **[Osprey Pharmaceuticals USA](https://millionrounds.com/company/osprey-pharmaceuticals-usa)** Series A · US · ospreypharma.com **$11M** With 5 others - **Jan** **[Sonexa Therapeutics](https://millionrounds.com/company/sonexa-therapeutics)** Series A · US · biospace.com **$30M** With 4 others - **2007** 3 rounds - **Nov** **[Ambit Biosciences](https://millionrounds.com/company/ambit-biosciences)** Series D · US **$49M** With 11 others - **Jan** **[Osprey Pharmaceuticals USA](https://millionrounds.com/company/osprey-pharmaceuticals-usa)** Venture · US **$5.9M** With 4 others - **Jan** **[Cytochroma](https://millionrounds.com/company/cytochroma)** Series C · US **$18M** With 2 others - **2006** 1 round - **Dec** **[Xanthus Pharmaceuticals](https://millionrounds.com/company/xanthus-pharmaceuticals)** Series B · US **$25M** With 9 others - **2005** 1 round - **May** **[Ambit Biosciences](https://millionrounds.com/company/ambit-biosciences)** Series C · US **$31M** With 6 others - **2003** 2 rounds - **Dec** **[Xanthus Pharmaceuticals](https://millionrounds.com/company/xanthus-pharmaceuticals)** Series B · US **$31M** With 10 others - **Jul** **[LymphoSign](https://millionrounds.com/company/lymphosign)** Series A · CA **$5.9M** With 1 other - **2001** 1 round - **Jul** **[NewBiotics](https://millionrounds.com/company/newbiotics)** Series C · US **$11M** With 5 others An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor. ## The team We hold **4** people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them. ## Exits from the portfolio Companies it backed that were later bought or listed **6 in all** **[Ambit Biosciences](https://millionrounds.com/company/ambit-biosciences)** Bought by [Daiichi Sankyo](https://millionrounds.com/fund/daiichi-sankyo) **$410M** Sept 2014 **[Conatus Pharmaceuticals](https://millionrounds.com/company/conatus-pharmaceuticals)** Listed **$69M** Jun 2013 **[Cytochroma](https://millionrounds.com/company/cytochroma)** Bought by [OPKO Health](https://millionrounds.com/fund/opko-health) **Undisclosed** Jan 2013 **[Xanthus Pharmaceuticals](https://millionrounds.com/company/xanthus-pharmaceuticals)** Bought by Antisoma **Undisclosed** May 2008 **[LymphoSign](https://millionrounds.com/company/lymphosign)** Bought by Aegera Therapeutics **Undisclosed** Aug 2007 **[NewBiotics](https://millionrounds.com/company/newbiotics)** Bought by Celmed Biosciences **Undisclosed** Jul 2004 An exit counts when it came after the firm's first round in the company. From historical deal records. ## The cheque Series B Series A Series C Median round joined **$20M** the round, not its cheque Led 0 of 21 rounds **0%** - **Sole investor:** Never alone - **Last cheque:** May 2014 - **Exits:** 6 from the portfolio Rounds by stage said on their site - Series B *9* - Series A *5* - Series C *4* - Series D *2* - Venture *1* Cheques by year Led Joined 2001 2014 Often in the room with - [Novartis Venture Fund](https://millionrounds.com/fund/novartis-venture-fund) 6 - [Athenian Venture Partners](https://millionrounds.com/fund/athenian-venture-partners) 4 - [BDC Capital](https://millionrounds.com/fund/bdc-venture-capital) 4 - [Gimv](https://millionrounds.com/fund/gimv) 4 - [Kearny Venture Partners](https://millionrounds.com/fund/kearny-venture-partners) 4 - [Triathlon Medical Venture Partners](https://millionrounds.com/fund/triathlon-medical-ventures) 4 **Pitching GeneChem?** Put them on your fundraising board with this record on the card, and follow them to hear when they write a new cheque. Add to your CRM *→* ## Who they invest alongside The investors most often in the same rounds as GeneChem. A count of rooms they were both in, not a relationship either has claimed. [**Novartis Venture Fund** Corporate VC **6** rounds together](https://millionrounds.com/fund/novartis-venture-fund)[**Athenian Venture Partners** VC firm **4** rounds together](https://millionrounds.com/fund/athenian-venture-partners)[**BDC Capital** VC firm **4** rounds together](https://millionrounds.com/fund/bdc-venture-capital)[**Gimv** Private equity **4** rounds together](https://millionrounds.com/fund/gimv)[**Kearny Venture Partners** VC firm **4** rounds together](https://millionrounds.com/fund/kearny-venture-partners)[**Triathlon Medical Venture Partners** Growth equity **4** rounds together](https://millionrounds.com/fund/triathlon-medical-ventures)[**Venture Investors** VC firm **4** rounds together](https://millionrounds.com/fund/venture-investors-health-fund)[**ARCH Venture Partners** VC firm **3** rounds together](https://millionrounds.com/fund/arch-venture-partners)[**CMEA Ventures** VC firm **3** rounds together](https://millionrounds.com/fund/cmea-capital)[**Forward Ventures** Accelerator **3** rounds together](https://millionrounds.com/fund/forward-ventures)[**Roche Venture Fund** Corporate VC **3** rounds together](https://millionrounds.com/fund/roche-venture-fund)[**Sigvion Capital** Growth equity **3** rounds together](https://millionrounds.com/fund/sigvion-capital) ## Quick answers about GeneChem ### What does GeneChem invest in? GeneChem invests most often at Series B and Series A (67% of the rounds on record), in sectors such as E-Commerce, Energy and Health Care. ### How active is GeneChem? 21 investments on record, 0 of them in the last 12 months. The most recent was in May 2014. ### How big are GeneChem's cheques? The median round it joins is $20M. ### Does GeneChem lead rounds? Rarely, if at all: none of its 21 investments on record names it as the lead. ### Where does GeneChem invest? Most of the companies it backs are in the United States (86%) and Canada (14%). ### Is GeneChem investing now? It looks quiet: no investment on record since May 2014. ### Who does GeneChem invest alongside? Most often Novartis Venture Fund (6 rounds together), Athenian Venture Partners (4 rounds together) and BDC Capital (4 rounds together). ### What kind of investor is GeneChem? GeneChem is a growth equity firm based in Montreal, Canada. ## Raising now? Find the investors who back rounds like yours, and keep every conversation on one fundraising board. Find similar investorsOpen your CRM Built from the rounds we watched, its filings and its own website, refreshed every night. [How we count](https://millionrounds.com/methodology) · [Report a correction](https://millionrounds.com/corrections?slug=genechem) · [Is this your firm? Claim it](https://millionrounds.com/claim?org=genechem)